Atenolol Tablets

It is a selective β1 adrenergic receptor blocker, without membrane stabilization and endogenous sympathomimetic activity. However, it does not inhibit the bronchodilator effect of isoproterenol. Its mechanism of lowering blood pressure and reducing myocardial oxygen consumption is the same as that of propranolol. Large-scale clinical trials have confirmed that atenolol can reduce the mortality rate of acute myocardial infarction within 0 to 7 days. The therapeutic dose has no significant inhibition on myocardial contractility. [Pharmacokinetics] Oral absorption is very fast, but not complete. Oral absorption is 50%, and the peak concentration is reached in 2 to 4 hours. The duration of action after oral administration is long, up to 24 hours. It is widely distributed in various tissues, and a small amount can pass through the blood-cerebrospinal fluid barrier. The distribution volume of healthy people is about 50~75L. The half-life in the blood is 6~7 hours, and it is mainly excreted in the urine in its original form. When renal function is impaired, the half-life is prolonged, and it can accumulate in the body and can be cleared during hemodialysis. This product has low lipid solubility, very low penetration into brain tissue, and extremely low plasma protein binding rate (6~16%).

The main ingredients of this product and their chemical names are: The main ingredient of this product is atenolol, and its chemical name is: 4-[3-[(1-methylethyl)amino-2-hydroxy]propoxy]phenylacetamide.

This product is a sugar-coated tablet, which appears white after removing the sugar coating.

It is mainly used to treat hypertension, angina pectoris, and myocardial infarction, and can also be used for arrhythmia, hyperthyroidism, and pheochromocytoma.

Oral: Adult usual dose: 6.25-12.5 mg each time, twice a day, gradually increase to 50-200 mg (2-8 tablets) as needed and tolerated. In case of renal impairment, if creatinine clearance is less than 15 ml/(min·1.73 m2), 25 mg (1 tablet) per day; if 15-35 ml/(min·1.73 m2), up to 50 mg (2 tablets) per day.

In patients with myocardial infarction, the most common adverse reactions are hypotension and bradycardia; other reactions may include dizziness, cold limbs, fatigue, weakness, gastrointestinal discomfort, depression, hair loss, thrombocytopenia, psoriasis-like skin reactions, psoriasis exacerbation, rash and dry eyes, etc. Rarely, it may cause heart block in sensitive patients.

1. Ⅱ to Ⅲ degree heart block. 2. Cardiogenic shock. 3. Sick sinus syndrome and severe sinus bradycardia.

Precautions for children: Children should start with a small dose of 0.25-0.5 mg/kg, twice a day. Pay attention to monitoring heart rate and blood pressure. Precautions for pregnancy and lactation: This product can pass the placental barrier and appear in the umbilical cord blood. There is a lack of research on the use of this drug in the first 3 months, and the possibility of fetal damage cannot be ruled out. Long-term use of this drug by pregnant women is related to intrauterine growth retardation of the fetus. This drug has a significant aggregation effect in breast milk, and lactating women should be cautious when taking it. Precautions for the elderly: The required dose can be reduced, especially for patients with renal decline.

When used in combination with other antihypertensive drugs and diuretics, their antihypertensive effect can be enhanced. Be especially cautious when using Class I antiarrhythmic drugs, verapamil, and anesthetics. β-blockers can aggravate the rebound of hypertension caused by discontinuation of clonidine. If the two drugs are used in combination, this drug should be discontinued a few days before discontinuation of clonidine. If this drug is used to replace clonidine, the course of β-blocker treatment should be started a few days after stopping taking clonidine.

Seal tightly and store at room temperature.

25mg

24 months

Zhejiang Sansheng Mandi Pharmaceutical Co., Ltd.

• Founded in:

  1997-10-27

• Address:

  No. 1, Wangjiashan Road, Qingshanhu Street, Lin'an District, Hangzhou City, Zhejiang Province

• Tax NO.:

  91330185253932420N

• Registered Funds:

  56.5 million yuan

• Website:

  Log in to view

• Email:

  Log in to view